Status:
COMPLETED
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
Lead Sponsor:
GlaxoSmithKline
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
Brief Summary
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
- Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
- Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.
- Exclusion criteria: None specified
Exclusion
Key Trial Info
Start Date :
October 25 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 19 2006
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT00316732
Start Date
October 25 2004
End Date
December 19 2006
Last Update
October 16 2017
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Exeter, Devon, United Kingdom, EX2 5DW
2
GSK Investigational Site
Plymouth, Devon, United Kingdom, PL6 8DH
3
GSK Investigational Site
Colchester, Essex, United Kingdom, CO4 5JL
4
GSK Investigational Site
Stevenage, Hertfordshire, United Kingdom, SG2 4AB